Indication
Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.

Medicine details

Medicine name:
axicabtagene ciloleucel (Yescarta)
SMC ID:
SMC2189
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Publication due date:
Q3 2019
SMC meeting date:
Q3 2019
Patient group submission deadline:
03 June 2019